bristol-myers squibb - Search News

News

Bristol Myers Squibb raises 2025 EPS guidance to $6.70-$7.00

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy.

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the impact of stiff competition in the pharmaceutical market. Adjusted earnings of $1.

Seeking Alpha · 2d

Bristol-Myers Squibb Is A Good Pick

Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here to find out why BMY stock is a Buy.

Reuters on MSN · 3d

Bristol Myers Posts Better-Than-Expected Quarterly Revenue on Strong Cancer Drug Sales

Sales of the company's cancer immunotherapy Opdivo were $2.3 billion in the quarter, compared with Wall Street forecasts of just under $2 billion. Sales of its older immunotherapy, Yervoy, were $624 million in the quarter, more than $100 million higher than analysts' forecasts.

Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession

Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.

Fierce Pharma2d

BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 trial starts

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Merit Medical Systems (MMSI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

15hon MSN

4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Netflix's new high, Bristol Myers outlook, Texas Instruments pops

As part of today's Market Minute, Brad Smith outlines some of the top stories of the trading session. Netflix (NFLX) stock ...

BMY Stock: Is A Post-Earnings Slump Likely?

Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...

BioSpace2d

Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results